“the demand for this will be quite high. So our expectation, as you will see a strong launch with this drug”

In context

“r next question comes from Louise Chen with Cantor. Your line is open. Louise Chen: Hi. Thank you for taking my question. I wanted to ask you about sotatercept, how you are preparing for that launch, what’s your go-to-market strategy and how quickly you expect uptake to be? Thank you. Rob Davis: Yeah. Louise, this is Rob. I will maybe jump-in and Caroline can add if I miss anything. I would tell you that we feel well-prepared. So, obviously, we have been working to ensure we have supply to be able to supply the market upon launch. But as we sit here today, given what is happening in the marketplace. So you are seeing warehousing of patients in anticipation of the launch of sotatercept in the United States. And from feedback from key opinion leaders and what we are hearing from the market, the demand for this will be quite high. So our expectation, as you will see a strong launch with this drug and I can tell you we have been invested and built an organization, we actually have a very focused group now in our U.S. -- within our U.S. business whose sole job is to manage this launch. And so, I think, we are both prepared from a commercial perspective and from a manufacturing perspective with the expectation, as I said that, this should go with a very strong quick uptake. And the other thing I would highlight is given the strength of the data, we do expect to see approval in Europe next year, which we originally thought would require a further study. So not only are we preparing in the United States, but we are also preparing in Europe as well and we feel good about both. But Caroline, anything you would want to add. Caroline Litchfield: No. I think you captured it Rob. Dean, anyth”